Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

NCT03674814 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Enzalutamide
DRUG: Relacorilant

Sponsor

University of Chicago

Collaborators

[object Object]
[object Object]